Literature DB >> 32207281

Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.).

Han Na Jang1, Hye Seung Jung2.   

Abstract

Entities:  

Year:  2020        PMID： 32207281      PMCID： PMC7090290          DOI： 10.3803/EnM.2020.35.1.194

Source DB:  PubMed          Journal:  Endocrinol Metab (Seoul)        ISSN： 2093-596X


× No keyword cloud information.
  4 in total

1.  Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Authors:  Julio Rosenstock; Ronnie Aronson; George Grunberger; Markolf Hanefeld; PierMarco Piatti; Pierre Serusclat; Xi Cheng; Tianyue Zhou; Elisabeth Niemoeller; Elisabeth Souhami; Melanie Davies
Journal:  Diabetes Care       Date:  2016-08-15       Impact factor: 19.112

Review 2.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

Review 3.  A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.

Authors:  Lalita Prasad-Reddy; Diana Isaacs
Journal:  Drugs Context       Date:  2015-07-09

4.  Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.

Authors:  Han Na Jang; Ye Seul Yang; Seong Ok Lee; Tae Jung Oh; Bo Kyung Koo; Hye Seung Jung
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.